Cambridge-based Constructive Bio has raised £43.4m in its Series A funding round.
- Founded in 2021, the company focuses on developing programmable molecules.
- The funding was led by Ahren, OMX Ventures, and Paladin Capital Group.
- Additional financial support came from Fine Structure Ventures and others.
- Total funding for the startup now amounts to $75m.
Constructive Bio, a synthetic genomics startup based in Cambridge, successfully secured £43.4 million through the first close of its Series A funding round. This financial milestone marks a significant step forward for the company founded in 2021, allowing it to expand its innovative research and development efforts. The funding was spearheaded by Ahren, OMX Ventures, and Paladin Capital Group, showcasing strong investor confidence in Constructive Bio’s potential to revolutionise the field of synthetic genomics.
Central to Constructive Bio’s mission is the development of programmable molecules through their unique genomics synthesis process. This cutting-edge technology aims to engineer molecules with novel properties and functions, which could play a crucial role in supporting pharmaceutical and therapeutic treatments. According to the company’s founder, Professor Jason Chin, Constructive Bio is distinguished by its capability to transform living cells into sustainable biofactories. This transformation enables the programming of the sequence, composition, and chemistry of proteins and new biopolymers, positioning the company at the forefront of biotechnological innovation.
The substantial investment not only highlights the pioneering nature of Constructive Bio’s technology but also underscores the collaborative synergy between its three foundational platforms: deeply recoded synthetic genomes, engineered cellular machinery, and new chemistry. Paul Conley, Managing Director at Paladin Capital, expressed his admiration for the company’s progress, emphasising the potential of Constructive Bio’s bioengineering and biomanufacturing platform technologies to yield breakthroughs in medicine, enzymes, and biomaterials.
In addition to the primary investors, the funding round also saw contributions from Fine Structure Ventures, +ND Capital, and Jonathan Milner, the founder of Abcam. This diverse pool of investors further reinforces the confidence in Constructive Bio’s trajectory and its capacity to deliver transformative solutions in biotechnology. Notably, the startup had previously raised £12.5 million in a seed round in August 2022, bringing its total funding to a commendable $75 million.
Constructive Bio’s recent funding acquisition underscores its leadership in synthetic genomics and positions it for continued innovation.
